EDITAS MEDICINE INC. - COMMON STOCK

Editas Medicine Announces First Quarter 2023 Results and Business Updates

05 May 2023 07:00:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data

01 May 2023 16:01:00 By Nasdaq GlobeNewswire

Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events

01 May 2023 06:45:00 By Nasdaq GlobeNewswire

Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease

27 Apr 2023 09:00:01 By Nasdaq GlobeNewswire

Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director

13 Apr 2023 09:00:01 By Nasdaq GlobeNewswire

Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer

08 Mar 2023 09:00:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates

22 Feb 2023 06:15:00 By Nasdaq GlobeNewswire

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update

15 Feb 2023 06:45:00 By Nasdaq GlobeNewswire

Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies

19 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Strategic Updates and Portfolio Reprioritization

09 Jan 2023 08:15:00 By Nasdaq GlobeNewswire

Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 06:30:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease

06 Dec 2022 06:30:00 By Nasdaq GlobeNewswire

Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease

01 Dec 2022 16:01:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

17 Nov 2022 07:15:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Third Quarter 2022 Results and Business Updates

02 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update

26 Oct 2022 06:30:00 By Nasdaq GlobeNewswire

Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting

13 Oct 2022 06:00:00 By Nasdaq GlobeNewswire

Editas Medicine to Participate in Upcoming Investor Conferences

01 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Second Quarter 2022 Results and Business Updates

03 Aug 2022 06:29:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease

27 Jul 2022 06:30:00 By Nasdaq GlobeNewswire